Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Once a day Trientine

PreclinicalSmall molecule

YYale University

Once a day Trientine is one of 2 small molecule programs targeting Wilson disease. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wilson DiseaseActive, not recruiting

Wilson DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Wilson Disease

#DrugCompanyPhaseTrials

Botox

RRevance Therapeutics, Inc.

Once a day Trientine

YYale University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wilson disease1 trial

Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease

Completed·YYale University·N/A·NCT01472874·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Once a day Trientine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Once a day Trientine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Once a day Trientine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYale University

Related News